ZyVersa is a clinical stage specialty biopharmaceutical company with two licensed proprietary product platforms invented by top tier research scientists at University of Miami Miller School of Medicine. Our focus is on renal and inflammatory diseases which have a global total addressable market of around $14.5 billion and $65 billion, respectively.
The lead candidate in our renal pipeline is a novel Phase 2a-ready cholesterol efflux mediator, VAR 200, for focal segmental glomerulosclerosis (FSGS), an orphan renal disease. Renal cholesterol and lipid accumulation that occurs in FSGS and other glomerular diseases, such as Alport syndrome and diabetic kidney disease, contributes to structural damage to the kidneys’ filtration system leading to protein leaking into the urine (proteinuria) and disease progression. VAR 200 mediates removal of excess renal cholesterol and lipids that damage the kidneys and has potential to reduce proteinuria and delay disease progression.
For treatment of inflammatory diseases, we are well positioned in the inflammasome space with a highly differentiated monoclonal antibody that inhibits inflammasome ASC (IC 100). Unlike NLRP3 inhibitors, which target only the NLRP3 inflammasome, by targeting ASC, IC 100 potentially inhibits twelve or more types of inflammasomes. This is expected to better control inflammation in numerous inflammatory diseases that are triggered by activation of more than one type of inflammasome. Likewise, by targeting ASC, IC 100 inhibits ASC specks which amplify and propagate inflammation in inflammatory diseases. IC 100 has strong indication expansion potential in a broad range of inflammatory diseases.
ZyVersa’s accomplished leadership team has deep pharmaceutical experience and proven success in R&D, commercialization, licensing, M&A, raising capital, and taking companies public. They are driven to serve the needs of all ZyVersa stakeholders: patients, health care providers, payors, and investors.